Our mission is developing novel, universal protein subunit vaccines for infectious agents that are a major public health concern worldwide. 

Our underlying technology is a revolutionary proteome mining platform for protein-antigen discovery called Proteomics-based Expression Library Screening (PELS).  This technology was developed at Massachusetts General Hospital / Harvard Medical School by our founder.

Our current targets include pathogens causing gastrointestinal diseases in humans and infectious agents causing veterinary diseases. 

PathoVacs is seeking collaborations for commercialization of our current vaccine targets.  In addition, PathoVacs provides contract protein antigen discovery services for a broad array of pathogens.